EcoDrugPlus

Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase), Tandem Duplicate 1

Ensembl ID : ENSOMEG00000012704
Gene Symbol: AKR1B1.1
1 Cross references
338 Possible Orthologues:

Aldose Reductase-Related Protein 1-Like

Ensembl ID : ENSOMEG00000012775
Gene Symbol: LOC112153982
3 Cross references
337 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSOMEG00000011788
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:

Alpha-1a Adrenergic Receptor

Ensembl ID : ENSOMEG00000011498
Gene Symbol: LOC112147982
3 Cross references
202 Possible Orthologues:

Alpha-1b Adrenergic Receptor-Like

Ensembl ID : ENSOMEG00000006166
Gene Symbol: LOC112152981
3 Cross references
191 Possible Orthologues:

Alpha-2a Adrenergic Receptor-Like

Ensembl ID : ENSOMEG00000007002
Gene Symbol: LOC112137475
3 Cross references
176 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSOMEG00000018593
Gene Symbol: LOC112148606
3 Cross references
174 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSOMEG00000001182
Gene Symbol: AOC1
3 Cross references
231 Possible Orthologues:

Amine Oxidase Copper Containing 2

Ensembl ID : ENSOMEG00000002776
Gene Symbol: AOC2
1 Cross references
403 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSOMEG00000006503
Gene Symbol: APP
4 Cross references
203 Possible Orthologues:

Amyloid-Beta A4 Protein-Like

Ensembl ID : ENSOMEG00000019469
Gene Symbol: LOC112154862
3 Cross references
205 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSOMEG00000005697
Gene Symbol: AR
3 Cross references
213 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).